Presentation Details:
• Title: IMV102, an in vivo BCMA-targeting CAR-T therapy, achieves durable tumor control in multiple myeloma models
• Session Title: Gene and Vector-Based Therapy
• Date and Time: April 19, 2026, 2:00 PM – 5:00 PM (PT)
• Location: Poster Section 12
• Poster Board Number: 20
• Presentation Number: 277
About Immunofoco
Founded in 2020, Immunofoco is a globally leading innovative cell therapy company aiming to deliver accessible treatments with long-term survival benefits for patients suffering from cancer and autoimmune diseases. Its lead program, IMC002 (CLDN18.2 CAR-T), is currently in a pivotal Phase III trial in China.
The company leverages a “dual-engine” growth model, advancing ex vivo CAR-T therapies for solid tumors and in vivo CAR-T therapies across hematologic malignancies, solid tumors, and autoimmune diseases, supported by proprietary technology platforms and the FOCO-CAR manufacturing platform.
For more information, please visit www.immunofoco.com.
